BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zometa zoledronic acid: Phase III data

In the Phase III Myeloma IX Study in 1,960 evaluable patients, Zometa significantly reduced the proportion of patients experiencing an SRE vs. Bonefos clodronate (27% vs. 35.3%, p=0.0004). Additionally, Zometa significantly improved...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >